Yubo International Biotech Limited Quick Ratio (MAGAA) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Yubo International Biotech Limited  (MAGAA)

Yubo International Biotech Limited's Quick Ratio

MAGAA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0 a new company low.

Within Medical Equipment & Supplies industry 203 other companies have achieved higher Quick Ratio than Yubo International Biotech Limited in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 4186 to 4401.

Explain Quick Ratio?
How much Cash & cash equivalents MAGAA´s has?
What are MAGAA´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MAGAA/financial-strength
https://api.csimarket.com/api/v1/companies/MAGAA/fundamentals
https://api.csimarket.com/api/v1/companies/MAGAA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
MAGAA Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 38.9 %
Y / Y Cash & cash equivalent Change -74.53 %
Quick Ratio MRQ 0
MAGAA's Total Ranking # 4401
Seq. Current Liabilities Change 6.67 %
Seq. Cash & cash equivalent Change -66.41 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 204
Healthcare Sector # 913
Overall Market # 4401


Quick Ratio Statistics
High Average Low
1.25 0.05 0
(Mar 31 2021)   (Feb 29 2020)




Financial Statements
Yubo International Biotech Limited's Current Liabilities $ 4 Millions Visit MAGAA's Balance sheet
Yubo International Biotech Limited's Cash & cash equivalent $ 0 Millions Visit MAGAA's Balance sheet
Source of MAGAA's Sales Visit MAGAA's Sales by Geography


Cumulative Yubo International Biotech Limited's Quick Ratio

MAGAA's Quick Ratio for the trailling 12 Months

MAGAA Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -25.73 %
Y / Y Cash & cash equivalent TTM Growth -69.55 %
Quick Ratio TTM 0.01
Total Ranking TTM # 4053
Seq. Current Liabilities TTM Growth 8.5 %
Seq. Cash & cash equivalent TTM Growth -28.57 %


On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q3 2026 to $3.55 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Yubo International Biotech Limited average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 207 other companies have achieved higher Quick Ratio than Yubo International Biotech Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 4006 to 4142.

Explain Quick Ratio?
How much Cash & cash equivalents MAGAA´s has?
What are MAGAA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 208
Healthcare Sector # 916
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
0.31 0.03 0
(Jun 30 2021)   (Nov 30 2017)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Equipment & Supplies Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Yubo International Biotech Limited 0.00 $ 0.009  Millions$ 3.549  Millions

Date modified: 2026-11-11T13:51:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.